within Pharmacolibrary.Drugs.ATC.C;

model C02KX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.94,
    Cl             = 0.058333333333333334,
    adminDuration  = 600,
    adminMass      = 0.0025,
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 2520
  );

  annotation(Documentation(
    info ="<html><body><p>Riociguat is a soluble guanylate cyclase (sGC) stimulator used for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is an orally administered, approved drug that functions by stimulating sGC, leading to vasodilation and reduced blood pressure in the pulmonary arteries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics of riociguat in healthy adult subjects after a single oral dose; both male and female participants, ages 18-45 years.</p><h4>References</h4><ol><li><p>Saleh, S, et al., &amp; Mück, W (2016). Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food. <i>Pulmonary circulation</i> 6(Suppl 1) S66–S74. DOI:<a href=&quot;https://doi.org/10.1086/685020&quot;>10.1086/685020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27162630/&quot;>https://pubmed.ncbi.nlm.nih.gov/27162630</a></p></li><li><p>Willmann, S, et al., &amp; Saleh, S (2023). Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension. <i>Pediatric pulmonology</i> 58(3) 908–917. DOI:<a href=&quot;https://doi.org/10.1002/ppul.26277&quot;>10.1002/ppul.26277</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36507572/&quot;>https://pubmed.ncbi.nlm.nih.gov/36507572</a></p></li><li><p>Saleh, S, et al., &amp; Mück, W (2016). Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment. <i>Pulmonary circulation</i> 6(Suppl 1) S75–S85. DOI:<a href=&quot;https://doi.org/10.1086/685647&quot;>10.1086/685647</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27162631/&quot;>https://pubmed.ncbi.nlm.nih.gov/27162631</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02KX05;
